Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

bioAffinity Technologies (BIAF) Total Current Liabilities (2022 - 2025)

Historic Total Current Liabilities for bioAffinity Technologies (BIAF) over the last 4 years, with Q3 2025 value amounting to $2.4 million.

  • bioAffinity Technologies' Total Current Liabilities fell 528.23% to $2.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.4 million, marking a year-over-year decrease of 528.23%. This contributed to the annual value of $3.1 million for FY2024, which is 3812.91% up from last year.
  • Per bioAffinity Technologies' latest filing, its Total Current Liabilities stood at $2.4 million for Q3 2025, which was down 528.23% from $2.6 million recorded in Q2 2025.
  • bioAffinity Technologies' Total Current Liabilities' 5-year high stood at $3.4 million during Q1 2025, with a 5-year trough of $775151.0 in Q2 2023.
  • Moreover, its 4-year median value for Total Current Liabilities was $2.2 million (2023), whereas its average is $2.0 million.
  • In the last 5 years, bioAffinity Technologies' Total Current Liabilities surged by 20010.77% in 2024 and then crashed by 528.23% in 2025.
  • Quarter analysis of 4 years shows bioAffinity Technologies' Total Current Liabilities stood at $1.1 million in 2022, then skyrocketed by 97.41% to $2.2 million in 2023, then surged by 38.13% to $3.1 million in 2024, then decreased by 24.0% to $2.4 million in 2025.
  • Its last three reported values are $2.4 million in Q3 2025, $2.6 million for Q2 2025, and $3.4 million during Q1 2025.